Healthcare services company Sotera Health (NASDAQ: SHC) will be reporting results this Tuesday before market open. Here’s what to expect.
Sotera Health Company beat analysts’ revenue expectations last quarter, reporting revenues of $321.4 million, up 9.2% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ organic revenue and EPS estimates.
Is Sotera Health Company a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Sotera Health Company’s revenue to grow 2.7% year on year, slowing from the 9.1% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Sotera Health Company has a history of exceeding Wall Street’s expectations.
Looking at Sotera Health Company’s peers in the research tools & consumables segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Avantor delivered year-on-year revenue growth of 4.6%, beating analysts’ expectations by 3.4%, and Thermo Fisher reported revenues up 9.1%, topping estimates by 1.4%. Avantor traded down 2.6% following the results while Thermo Fisher was also down 1.6%.
Read our full analysis of Avantor’s results here and Thermo Fisher’s results here.
There has been positive sentiment among investors in the research tools & consumables segment, with share prices up 3.2% on average over the last month. Sotera Health Company is down 2.2% during the same time and is heading into earnings with an average analyst price target of $22.61 (compared to the current share price of $18.14).
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
